Q1 FY27 Investor Presentation Outlines Growth and M&A Plans

Promoter Disclosed Acquisition PlansOrder Pipeline DisclosedInvestor Communications View source PDF Explain this filing

3BBLACKBIO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

-6.4%1-day move

₹1224.00

prior close

₹1181.20

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

-0.8-0.4-1.1-1.3-6.4-6.0-6.3-5.2-2.1—————

Up moveDown movePending

AI summary

Consolidated Q1 FY27 revenue rose 50.6% to Rs 3,349.08 lakh (includes Coris BioConcept Belgium). PAT fell 29% to Rs 897.84 lakh and EPS dropped to Rs 10.48 due to Coris negative EBITDA of Rs 352.24 lakh. Excluding Coris, revenue grew 11.8% to Rs 2,486.24 lakh, PAT up 8.2%, EPS at Rs 15.96. MDx division revenue grew 17.4% ex-Coris; exports up 38% to Rs 596.28 lakh. Company targets 15-20% growth for FY27. Confirmed HAT order of EUR 1.41M and Belgium govt order worth EUR 6M over 4 years. Actively seeking M&A in EU and US IVD space.

Likely market impact

Strong top-line growth but margins compressed by Coris integration losses. M&A plans may add future value but carry execution and integration risk.